News

Ipi4 trial registered at clinicaltrials.gov

The national phase IV trial with the drug ipilimumab (YervoyTM) has been registered on clinicaltrials.gov.

150 patients included in the Ipi4 trial; the trial is closed for further inclusion

The national phase IV trial with the drug ipilimumab (YervoyTM), known as the Ipi4 trial, is for patients with advanced melanoma who may benefit from the drug ipilimumab.

The trial is based at NorCRIN and involves five university hospitals (OUS, Haukeland, Stavanger, St. Olav and UNN) in addition to Ålesund Hospital, Hospital of Southern Norway Kristiansand and Nordland Hospital Bodø. The goal was to include 100 patients in the trial. The trial has been expanded with 50 additional patients, and was closed for inclusion in March 2014.